SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Anticipation of VK2735 subcutaneous maintenance-trial data is driving attention, with traders focused on whether weight loss is durable, dosing frequency can be reduced, and tolerability remains competitive with leading GLP-1 therapies. Bullish participants expect strong results to support a partnership or acquisition narrative, while skeptics emphasize the studys limited size, clinical uncertainty, dilution risk, and potential for a sell-the-news reaction.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Anticipation of Teslas invite-only Cybercab event and related robotaxi developmentsincluding additions to the Texas fleet and Austin service expansionis driving attention, with traders also citing Optimus and FSD updates. Bulls expect continued momentum and possible short covering, while skeptics argue the event is priced in and could become a sell-the-news catalyst amid concerns about autonomy, valuation, and execution.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

New real-world payment and settlement partnerships are driving attention, including Amalfi Jets planned acceptance of cryptocurrency through a Keeta wallet and the broader Visa Direct and ASK Group initiatives. Traders view these developments as validation of Keetas financial-rails strategy, while skeptics remain concerned about execution, limited network usage, and the lingering effects of the security breach.

Edison International is a renewable energy company, which operates through its subsidiaries. It supplies and distributes electric power, and also invests in energy services and technologies. The company was founded on July 4, 1886, and is headquartered in Rosemead, CA.

Edison International

California lawmakers wildfire legislation failed to provide the liability protections investors expected, leaving Edison International exposed to potentially significant wildfire claims and prompting analyst downgrades. Traders are divided between viewing the selloff as an overreaction and warning that unresolved liability, credit risk, and possible dividend pressure could prolong the weakness.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Bitcoin-led crypto momentum is driving attention to Coinbase, with traders viewing the exchange as a high-beta proxy for rising crypto prices, activity, and potential short covering. Bulls expect the rally to continue, while skeptics point to Coinbases weaker relative performance, sharp volatility, and risk of a pullback.

Corvex, Inc. is an AI cloud computing company, which specializes in GPU-accelerated infrastructure for AI workloads. Its products include GPU Clusters, Confidential Computing, Inference as a Service and GPU Node. The firm offers solutions include AI model builders, enterprises, federal and sovereign solutions. The company was founded by Seth Mitchell Demsey, Jay Crystal on October 21, 2024 and is headquartered in Arlington, VA.

Corvex Inc.

Movano Inc

Corvexs announced expansion of its AI data-center capacity and multi-year agreement to provide NVIDIA Blackwell GPU clusters to an AI customer is driving attention, as traders view the deal as a major shift from Movanos wearable-health business toward AI infrastructure. The community is largely bullish on momentum and a potential short squeeze, while skeptics cite the discounted private placement, dilution risk, and execution uncertainty.

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and personal computers, including smart phones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The company was founded by Ryan A. Brant in 1993 and is headquartered in New York, NY.

Take-Two Interactive Software, Inc.

Alleged Grand Theft Auto VI gameplay and build leaks are driving the selloff, with traders debating whether they signal unfinished gameplay, performance issues, a delay, or limited damage because the footage may be outdated and could amplify publicity. Bullish participants view the weakness as a buying opportunity ahead of the launch and Netflix preview, while skeptics argue expectations and GTA VI monetization are already priced in.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

Renewed pressure on long-dated Treasuries, driven by hawkish Federal Reserve signals, persistent inflation and oil concerns, and heavy fiscal borrowing, is keeping TLT in focus. Traders are divided over Treasury buyback efforts: bulls anticipate support and a short squeeze, while bears argue the intervention will be temporary and that structural debt and supply pressures will keep yields elevated.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

A broad crypto rebound, including stronger Bitcoin activity, is driving attention as traders expect higher crypto trading volumes and revenue for Robinhood, alongside growing interest in Robinhood Chain and prediction markets. Bulls view these businesses as major growth catalysts, while skeptics point to HOODs volatility, resistance levels, and frequent underperformance versus other crypto-linked stocks.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

Hawkish Federal Reserve messaging at Jackson Hole, rising Treasury yields, and increased expectations for a rate hike are pressuring small caps and driving bearish positioning in IWM. Traders are focused on heavy put activity and failed support levels, while some bulls argue that technical support could spark a rebound, leaving the conversation centered on downside risk versus a relief bounce.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Unusual volatility and bursts of volume/options activity are driving attention, with traders speculating about short covering or a potential squeeze despite no confirmed company announcement. The debate centers on whether momentum can persist ahead of DM1/FSHD and sirolimus updates, while skeptics point to delayed milestones, softer Elevidys demand and continued range-bound trading.

Sarepta Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, Sept. 14, at 8:30 a.m. ET. The presentation will...

SRPT On Track For Best Week In 5 Months Ahead Of Late-2026 Clinical Data — Retail Eyes ‘Monumental Comeback’

Equity

Investors are now awaiting extra data from Sarepta’s mid-stage studies in two muscle diseases, facioscapulohumeral muscular dystrophy and myotonic dystrophy.


KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak

Keros gets a $20M Takeda milestone, boosting cash and flexibility, but weak revenue visibility keeps collaboration income in focus.

Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?

Keros' rinvatercept pipeline offers upside, but zero quarterly revenue, clinical risk and a premium valuation make the stock a cautious bet.

Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (KSF), announces that KSF has commenced an investigation into Sarepta Therapeutics, Inc. (NasdaqGS: SRPT) (Sarepta or the Company).Sarepta is a biopharmaceutical company focused on...

Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated

SRPT beat Q2 earnings and revenue estimates despite weaker Elevidys sales, while narrowing its 2026 product revenue outlook and tightening expense guidance.

Sarepta Therapeutics (SRPT) Q2 Earnings and Revenues Surpass Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of +10.35% and +12.85%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Compared to Estimates, Sarepta Therapeutics (SRPT) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Sarepta Therapeutics (SRPT) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter of 2026. As I begin my tenure as CEO, I am excited by the strength of Sarepta's foundation, the impact our therapies are having for patients...

ANI Pharmaceuticals (ANIP) Reports Next Week: Wall Street Expects Earnings Growth

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

• Reported GAAP EPS of -$0.05 down -102.49% YoY
• Reported revenue of $401.25M down -34.34% YoY
• Sarepta Therapeutics narrowed its 2026 total net product revenue guidance to $1.2-$1.3 billion and narrowed combined non-GAAP R&D and SG&A expense guidance to $800.0-$850.0 million for the full year.

Sarepta Therapeutics experienced a 34% revenue decline due to lower ELEVIDYS sales, incurred a $39 million litigation charge, and faces ongoing regulatory and commercial adoption risks for its product portfolio.

Sarepta Therapeutics achieved quarterly operating profitability, appointed a new CEO with extensive industry experience, and strengthened its financial position with a $197 million increase in cash and investment holdings.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

SRPT Sarepta Therapeutics Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest SRPT News